Castle Biosciences Stock Price, News & Analysis

Castle Biosciences, Inc. (CSTL) announces the publication of a study validating the DecisionDx-UMSeq panel, enhancing uveal melanoma diagnostics. This 7-gene test leverages next-generation sequencing to identify critical somatic mutations from a single biopsy. Results show 100% positive agreement for single nucleotide variants and high technical prediction values. The combined use of DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMSeq allows for comprehensive tumor profiling, aiding in better-informed patient care and management decisions.

Castle Biosciences (CSTL) expects 2021 revenue to meet or exceed $93 million. The company delivered 28,118 gene expression profile test reports in 2021, a 55% increase from the previous year. Notable fourth-quarter performance included 8,242 reports, with 5,635 DecisionDx-Melanoma reports (up 33%). Despite a decline in melanoma diagnoses, Castle's investments in growth initiatives are reflected in these results. Year-end cash and equivalents are projected at $330 million.

Castle Biosciences, Inc. (Nasdaq: CSTL) announced that CEO Derek Maetzold and CFO Frank Stokes will present at the 24th Annual Needham Growth Conference on January 10, 2022, at 12:30 p.m. Eastern time. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for two weeks thereafter. Castle Biosciences specializes in personalized diagnostics for diseases such as skin cancer and has an innovative test development pipeline aimed at improving treatment outcomes.

Castle Biosciences has announced the acquisition of Cernostics for approximately $30 million, with potential additional payments of up to $50 million based on milestones. This acquisition enables Castle to expand into the gastrointestinal market through the TissueCypher® Barrett’s Esophagus Assay, aimed at predicting high-grade dysplasia and esophageal cancer in Barrett’s esophagus patients. The deal is expected to add roughly $1 billion to Castle's U.S. total addressable market (TAM).

Castle Biosciences, Inc. (NASDAQ: CSTL) presented its DecisionDx® gene expression profile tests for skin cancer at the American Society for Dermatologic Surgery 2021 Annual Meeting (Nov. 19-21, 2021). These tests, including DecisionDx-Melanoma and DecisionDx-SCC, aim to enhance personalized treatment decisions and patient outcomes. Key findings indicated that integrating genetic data with clinical features can better predict metastasis and recurrence risks. The studies support the clinical utility of these tests in managing melanoma and cutaneous squamous cell carcinoma.

Castle Biosciences (NASDAQ:CSTL) announced a study showcasing its DecisionDx-Melanoma test's predictive capabilities in cutaneous melanoma. The study, involving 438 patients, revealed that those classified as Class 1A (low risk) achieved a remarkable five-year recurrence-free survival rate of 95.8% and a distant metastasis-free survival rate of 99.2%. This underscores the test's role in aiding personalized treatment decisions and improving patient outcomes, with significant independent predictive value over traditional staging methods.

Castle Biosciences, Inc. (Nasdaq: CSTL) will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, Nov. 18, 2021, at 9:30 a.m. Eastern time. CEO Derek Maetzold and CFO Frank Stokes will share insights about the company’s innovative diagnostics aimed at improving patient outcomes. Live audio webcasts will be available on the company’s website, with replays accessible for two weeks post-event. Castle specializes in personalized genomic information for better treatment decisions in cancers like melanoma.